Revolutionizing peptide‐based drug discovery: Advances in the post‐AlphaFold era

Abstract

Peptide‐based drugs offer high specificity, potency, and selectivity. However, their inherent flexibility and differences in conformational preferences between their free and bound states create unique challenges that have hindered progress in effective drug discovery pipelines. The emergence of AlphaFold (AF) and Artificial Intelligence (AI) presents new opportunities for enhancing peptide‐based drug discovery. We explore recent advancements that facilitate a successful peptide drug discovery pipeline, considering peptides' attractive therapeutic properties and strategies to enhance their stability and bioavailability. AF enables efficient and accurate prediction of peptide‐protein structures, addressing a critical requirement in computational drug discovery pipelines. In the post‐AF era, we are witnessing rapid progress with the potential to revolutionize peptide‐based drug discovery such as the ability to rank peptide binders or classify them as binders/non‐binders and the ability to design novel peptide sequences. However, AI‐based methods are struggling due to the lack of well‐curated datasets, for example to accommodate modified amino acids or unconventional cyclization. Thus, physics‐based methods, such as docking or molecular dynamics simulations, continue to hold a complementary role in peptide drug discovery pipelines. Moreover, MD‐based tools offer valuable insights into binding mechanisms, as well as the thermodynamic and kinetic properties of complexes. As we navigate this evolving landscape, a synergistic integration of AI and physics‐based methods holds the promise of reshaping the landscape of peptide‐based drug discovery.This article is categorized under: Structure and Mechanism > Computational Biochemistry and Biophysics Molecular and Statistical Mechanics > Molecular Interactions Software > Molecular Modeling

Scaffold-Lab: Critical Evaluation and Ranking of Protein Backbone Generation Methods in A Unified Framework

“…Designing extremely short and large proteins holds particularly utility in specific contexts, such as the former conductive for some peptide drugs 75 or mini-binders 76,77 and the latter for large multi-domain proteins 78 or symmetrical protein assemblies 79,80 . While a number of peptide 81 and binder design 82 methods have been proposed to address these needs, the design of large proteins remains an enduring challenge.…”

A Computational Pipeline for Accurate Prioritization of Protein‐Protein Binding Candidates in High‐Throughput Protein Libraries

“…We find this approach promising to improve drug discovery efforts. [44,50] For systems that are amenable to this technique (see AF and AF-CBA limitations), the three-stage pipeline allows us to screen peptide libraries with thousands of candidates against a particular receptor in a reasonable amount of time, identifying the best peptide candidate and providing a path for querying peptide therapeutics. It also…”